FebriDx®: A Rapid Diagnostic Test for Differentiating Bacterial and Viral Aetiologies in Acute Respiratory Infections
- 13 Downloads
FebriDx® is a rapid, point-of-care diagnostic test that is designed to aid in the differentiation of bacterial and viral acute respiratory infections (ARIs), thus helping to guide decisions regarding the prescription of antibiotics in the outpatient setting. FebriDx carries a CE mark for use in the EU and is also approved in several other countries, including Canada, Saudi Arabia and Singapore. It is indicated for use in patients > 2 years old with symptoms consistent with a community-acquired ARI. The test involves the use of an immunoassay on a fingerstick blood sample to provide simultaneous, qualitative measurement of elevated levels of C-reactive protein (CRP) and myxovirus resistance protein A (MxA). In two prospective, multicentre studies in patients with acute upper respiratory tract infections, FebriDx was shown to be both sensitive and specific in identifying patients with a clinically significant infection and in differentiating between infections of bacterial and viral aetiology. The test is simple, requires no additional equipment and produces actionable results in ~ 10 min. As was demonstrated in a small, retrospective analysis, FebriDx results can help guide (improve) antibiotic prescribing decisions. Reducing the unnecessary or inappropriate prescription of antibiotics for ARIs of probable viral aetiology is important for antibiotic stewardship and can also reduce the unnecessary exposure of patients to the risk of antibiotic-related adverse events. FebriDx thus represents a useful diagnostic tool in the outpatient setting.
During the peer review process, the manufacturer of FebriDx was also offered an opportunity to review this article. Changes resulting from comments received were made on the basis of scientific and editorial merit.
Compliance with Ethical Standards
The preparation of this review was not supported by any external funding.
Conflict of interest
Matt Shirley is a salaried employee of Adis International Ltd/Springer Nature, is responsible for the article content and declares no relevant conflicts of interest.
- 8.World Health Organization. Antibiotic resistance; 2018. http://www.who.int/en/news-room/fact-sheets/detail/antibiotic-resistance. Accessed 20 Sep 2019.
- 11.US Centers for Disease Control and Prevention. Antibiotic use in the United States, 2017: progress and opportunities; 2017. http://www.cdc.gov/antibiotic-use/stewardship-report/pdf/stewardship-report.pdf. Accessed 20 Sep 2019.
- 15.Rodrigues CMC, Groves H. Community-acquired pneumonia in children: the challenges of microbiological diagnosis. J Clin Microbiol. 2018;56(3):article e01318-17, 1–9.Google Scholar
- 16.RPS Diagnostics. FebriDx®: product brochure; 2018. http://www.rpsdetectors.com/wp-content/uploads/2018/11/FRM-MKT-361.5_FebriDx-Brochure_Final.pdf. Accessed 20 Sep 2019.
- 17.RPS Diagnostics. FebriDx® receives updated CE mark to allow incorporation of all-in-one test format [media release]. 31 Oct 2018. http://www.rpsdetectors.com/wp-content/uploads/2018/10/18-1031_FebriDx_NewFormat_CE-Mark.pdf.
- 18.RPS Diagnostics. FebriDx®; 2019. http://febridx.com. Accessed 20 Sep 2019.
- 19.RPS Diagnostics. FebriDx®: quick reference guide; 2018. http://www.rpsdetectors.com/wp-content/uploads/2018/11/AP0067.1_FebriDxQuickReference-Guide_Final.pdf. Accessed 20 Sep 2019.
- 26.Le Bel J, Hausfater P, Chenevier-Gobeaux C, et al. Diagnostic accuracy of C-reactive protein and procalcitonin in suspected community-acquired pneumonia adults visiting emergency department and having a systematic thoracic CT scan. Crit Care. 2015;19(366):1–12.Google Scholar
- 39.Davidson M. FebriDx point-of-care testing to guide antibiotic therapy for acute respiratory tract infection in UK primary care: a retrospective outcome analysis. J Infect Dis Prev Med. 2017;5(3):1000165.Google Scholar
- 41.National Institute for Health and Care Excellence (NICE). Pneumonia in adults: diagnosis and management; 2014. http://www.nice.org.uk/guidance/cg191. Accessed 20 Sep 2019.